PRESCRIPTION MEDICATIONS ONLINE PHARMACY

.
.
.
.
.
.
.
.
.
.
.

<p>PRX) today reported fourth quarter and full year 2008 results <a href="http://annodex.org/wiki/User:Torivholtn">generic prilosec</a> ended. This is compared with reported revenues of $769.7 million generic lotrimin and income acai berry and with celexa from continuing operations of $51.1 million, or $1.47 per <a href="http://billrob.com/members/emilyuweeksw.aspx?genericsingulair">buspirone</a> diluted share, for 2007. By comparison, fourth generic periactin quarter 2007 results included a pre-tax gain of antibiotic tazar $3.1 million from Par's sale of its remaining investment in Optimer Pharmaceutical, champix Inc. </p>

<p>This is compared with reported rheumatoid arthritis treatment revenues of $155.1 million and income from continuing operations of $5.5 million, or $0.16 per diluted share, for the same period <a href="http://nickj.org/User:Janylbishoph">chemist</a> in 2007. rosiglitazone generic amoxil For the fourth quarter ended , Par reported total revenues of $161.3 million and a loss from continuing raloxifene operations of $30.5 million, or $0.91 per share. </p>

<p>Adjusting antibiotic mechanisimpps q mechanismppt mechanisimpp <a href="http://moodle.pteppic.net/demosite03/user/view.php?id=4068&course=1&t=prescriptionmedicines">prescription medicines</a> for these items, income from continuing operations for the fourth quarter of 2007 would have been $6.5 generic digitek million, or $0.19 per diluted share. Adjusting for these items and other special items, income from continuing generic zocor operations for the fourth quarter 2008 would have been $7.1 million, or $0.21 per diluted <a href="http://touhoumon.internetlantic.com/wiki/index.php?title=User:Cleoupearsony">generic pletal</a> share. </p>

<p>Fourth quarter 2008 reported, or GAAP, loss from continuing operations also included the write-off of a restructuring charge of $15.4 million and ventolin aerosol other related costs of $3.8 million, $49.2 million in charges due to an unfavorable court decision and related legal fees, $5.3 million zoloft online gain on non-core ANDA sales and the sale coreg of other product rights, $4.9 million impairment charge related to various investments, and amoxicillin antibiotic a $7.9 million gain related to richmound debt extinguishment. Par Pharmaceutical Reports Fourth Quarter and Full Year 2008 Results





WOODCLIFF LAKE, N.J., / - / -- omnicef antibiotic cost Par Pharmaceutical Companies, Inc. For the year ended , Par reported total revenues of $578.1 million and a loss from continuing operations of $45.9 million, or $1.38 per share. </p>

<p>Par's reported, or GAAP, loss from continuing operations for the year ended , included the write-off of an intangible asset apo metoprolol hair loss and certain inventories related to the trimming of its generic product portfolio of $5.5 million, a charge related to a government pricing contingency of $4.8 million, a $7.8 million net impairment charge related to various investments, $7.5 million in development. <p>Com stock and $4.6 million of additional share-based compensation expense related to Par's employee stock option tender offer. </p>

---